There are currently 1271 clinical trials in Miami, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Miami, GSK Investigational Site, University of Miami Miller School of Medicine-Sylvester Cancer Center and University of Miami Miller School of Medicine. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Serum Endotoxin Assay to Predict the Development of Postoperative Infectious Complications and Systemic Inflammatory Response Following Percutaneous Nephrolithotomy.
NCT04669886
Recruiting
The aim of the study is to establish an infectious risk stratification system based on pre-and post-operative blood endotoxin profile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2024
Locations: University of Miami, Miami, Florida
Conditions: Nephrolithiasis, Urosepsis
Register for Updates
Evaluating the Bacterial and Fungal Microbiome in Patients With Calcium Oxalate Urolithiasis and Renal Cell Carcinoma
NCT04669860
Recruiting
The purpose of the study is to identify bacterial and fungal microbiome associated with calcium oxalate (CO) urolithiasis and renal cell carcinoma (RCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2024
Locations: University of Miami, Miami, Florida
Conditions: Calcium Oxalate Urolithiasis, Renal Cell Carcinoma
Register for Updates
Single and Combined Effects of Behavioral, Academic, and Medication Treatments for ADHD in the Classroom
NCT05469386
Recruiting
This study is the first to systematically evaluate the efficacy of single and combined academic accommodation, behavioral treatment, and medication treatment in a large sample of children with ADHD. Using a scientifically rigorous, cross-over design the impact of these approaches on ecologically valid measures of outcome (on-task behavior, quiz scores, academic productivity) will be assessed to inform effective school intervention.
Gender:
ALL
Ages:
Between 5 years and 12 years
Trial Updated:
09/04/2024
Locations: FIU Center for Childern and Families, Miami, Florida
Conditions: ADHD
Register for Updates
Clinical Applications of Advanced Ophthalmic Imaging
NCT03135327
Recruiting
The purpose of this study is to determine the clinical application of advanced ophthalmic imaging devices such as optical coherence tomography (OCT), retinal function imager (RFI), slit-lamp biomicroscopy (SLB), PERG in diseased eyes and normal controls. There are two phases in this study. The first phase is an observational phase which studies the eye in various conditions. The second phase is an interventional phase which studies the changes in the eyes after taking an over-the-counter medica... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
09/03/2024
Locations: Bascom Palmer Eye Institute, Miami, Florida
Conditions: Multiple Sclerosis, Dry Eye Syndromes, Diabetic Retinopathy, Presbyopia, Myopia, Dementia
Register for Updates
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
NCT05959291
Recruiting
The purpose of this preliminary research study is to see if patients discontinuing maintenance Herceptin and/or other anti-HER-2 treatments with monitoring in addition to radiologic imaging and routine blood work will stay in complete radiological remission and to determine how long patients are able to stay in complete radiological remission without treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/03/2024
Locations: University of Miami, Miami, Florida
Conditions: HER2-positive Metastatic Breast Cancer, Stage IV Breast Cancer
Register for Updates
PAP for Children With DS and OSAS
NCT04132999
Recruiting
Determine the efficacy of family-informed intervention (INT) vs standard clinical care over a period of twelve months in children with obstructive sleep apnea and Down Syndrome.
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
09/03/2024
Locations: University of Miami, Miami, Florida
Conditions: Down Syndrome, Obstructive Sleep Apnea
Register for Updates
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
NCT02074839
Recruiting
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where four cohorts of pati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/03/2024
Locations: University of Miami, Miami, Florida
Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
Register for Updates
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
NCT06376526
Recruiting
The purpose of this study is to determine whether Linvoseltamab therapy in patients with newly diagnosed multiple myeloma will convert the disease status from minimal residual disease (MRD)-positive to MRD-negative, and increase the length of time that the disease is controlled. The researchers also want to find out the effects (good and bad) that Linvoseltamab has on participants and the condition.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/03/2024
Locations: University of Miami, Miami, Florida
Conditions: Multiple Myeloma
Register for Updates
Safety Study of PP-007 in Subjects With Acute Ischemic Stroke
NCT04677777
Recruiting
The HEMERA-1 Extension (Part III) is a prospective, open-label, multicenter study to evaluate safety of two doses of PP-007 in Acute Ischemic Stroke (AIS) subjects receiving Intravenous Thrombolysis (IVT) or mechanical thrombectomy (MT) or IVT+MT as standard of care (SOC). Subjects will receive two doses of PP-007 infusion 24 ± 6 hours apart in addition to the site-specific SOC protocol. PP-007 is PEGylated bovine carboxyhemoglobin and will be administered via IV infusion. The effects on collate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2024
Locations: Baptist Health Miami Cardiac & Vascular Institute (MCVI), Miami, Florida
Conditions: Acute Ischemic Stroke
Register for Updates
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
NCT05870748
Recruiting
A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Baptist Health South Florida (BHSF) - Miami Cancer Institute, Miami, Florida
Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
Register for Updates
64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)
NCT05633160
Recruiting
The aim for this study is to determine the safety and efficacy of 67Cu-SAR-BBN in participants with Gastrin Releasing Peptide Receptor (GRPR)-expressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with 177Lu-PSMA-617.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Biogenix Molecular, Miami, Florida
Conditions: Prostatic Neoplasms, Castration-Resistant
Register for Updates
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
NCT05797805
Recruiting
This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation,optimization, and expansion study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy. In the second part of the study, the combination of tegavivint plus pembrolizumab will be assessed with a limited dose escalation followed by a randomized dose optimization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: Sylvester Comprehensive Cancer Center, Miami, Florida
Conditions: Advanced Hepatocellular Carcinoma
Register for Updates